{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:00:18Z","timestamp":1792432818361,"version":"4.5.0"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2504700"],"award-info":[{"award-number":["2022YFC2504700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22105137, 82172634"],"award-info":[{"award-number":["22105137, 82172634"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M683324, 2022T150449"],"award-info":[{"award-number":["2020M683324, 2022T150449"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICI) therapy based on programmed cell death-1 (PD-1) and programmed cell death ligand 1 (PD-L1) has changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC) and improved the survival expectancy of patients. However, it also leads to immune-related adverse events (iRAEs), which result in multiple organ damage. Among them, the most common one with the highest mortality in NSCLC patients treated with ICI is checkpoint inhibitor pneumonitis (CIP). The respiratory signs of CIP are highly coincident and overlap with those in primary lung cancer, which causes difficulties in detecting, diagnosing, managing, and treating. In clinical management, patients with serious CIP should receive immunosuppressive treatment and even discontinue immunotherapy, which impairs the clinical benefits of ICIs and potentially results in tumor recrudesce. Therefore, accurate diagnosis, detailedly dissecting the pathogenesis, and developing reasonable treatment strategies for CIP are essential to prolong patient survival and expand the application of ICI. Herein, we first summarized the diagnosis strategies of CIP in NSCLC, including the classical radiology examination and the rising serological test, pathology test, and artificial intelligence aids. Then, we dissected the potential pathogenic mechanisms of CIP, including disordered T cell subsets, the increase of autoantibodies, cross-antigens reactivity, and the potential role of other immune cells. Moreover, we explored therapeutic approaches beyond first-line steroid therapy and future direction based on targeted signaling pathways. Finally, we discussed the current impediments, future trends, and challenges in fighting ICI-related pneumonitis.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1138483","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T05:00:33Z","timestamp":1680584433000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies"],"prefix":"10.3389","volume":"14","author":[{"given":"Xinyu","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31601-x","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (Keynote-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint hla-E:Cd94-Nkg2a mediates evasion of circulating tumor cells from nk cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955920","article-title":"Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"150932","DOI":"10.1016\/j.soncn.2019.08.011","article-title":"Immune checkpoint inhibitors in lung cancer and melanoma","volume":"35","author":"Madden","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663986","article-title":"Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: Current understanding in characteristics, diagnosis, and management","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40425-018-0382-2","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (Nsclc)","volume":"6","author":"Brahmer","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-Pd-1 and anti-Pd-L1 drugs: Systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00333-8","article-title":"Treatment-related adverse events of pd-1 and pd-L1 inhibitor-based combination therapies in clinical trials: A systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.20892\/j.issn.2095-3941.2020.0102","article-title":"The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients","volume":"17","author":"Zhai","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2407","article-title":"Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis","volume":"8","author":"Cao","year":"2019","journal-title":"Cancer Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103538","article-title":"Which treatment after first line therapy in nsclc patients without genetic alterations in the era of immunotherapy","volume":"169","author":"Insa","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.793831","article-title":"Improvement of pd-1 blockade efficacy and elimination of immune-related gastrointestinal adverse effect by mtor inhibitor","volume":"12","author":"Bai","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-Ctla-4 antibodies: Systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis","volume":"9","author":"Chuzi","year":"2017","journal-title":"Cancer Manag Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11912-020-00920-z","article-title":"Checkpoint inhibitor pneumonitis: Mechanisms, characteristics, management strategies, and beyond","volume":"22","author":"Reuss","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer: Benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-Small-Cell lung cancer (Checkmate 012): Results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-225937","article-title":"Severe pneumonitis refractory to steroids following anti-Pd-1 immunotherapy","volume":"2018","author":"Andruska","year":"2018","journal-title":"BMJ Case Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920922033","article-title":"Association of immune-related pneumonitis with the efficacy of pd-1\/Pd-L1 inhibitors in non-small cell lung cancer","volume":"12","author":"Cui","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"Egfr-Tki-Associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11618","article-title":"Elevated levels of il-17a and il-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer","volume":"20","author":"Wang","year":"2020","journal-title":"Oncol Lett"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.02.018","article-title":"Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-Small-Cell lung cancer","volume":"20","author":"Voong","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.830631","article-title":"Checkpoint inhibitor pneumonitis induced by anti-Pd-1\/Pd-L1 therapy in non-Small-Cell lung cancer: Occurrence and mechanism","volume":"13","author":"Yin","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: Esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American thoracic Society\/European respiratory society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-1320","article-title":"Pd-1 inhibitor-related pneumonitis in advanced cancer patients: Radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-2033","article-title":"Anti-Pd1-Induced pneumonitis: Capturing the hidden enemy","volume":"22","author":"Castanon","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","article-title":"The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors","volume":"39","author":"Jia","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.698832","article-title":"Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.827199","article-title":"Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8526-3","article-title":"The role and immunobiology of eosinophils in the respiratory system: A comprehensive review","volume":"50","author":"Eng","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/Programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/his.14704","article-title":"Immune check-point inhibitor-related pneumonitis: Acute lung injury with rapid progression and organising pneumonia with less severe clinical disease","volume":"81","author":"Imran","year":"2022","journal-title":"Histopathology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1038\/s41467-020-17971-2","article-title":"Artificial intelligence for the detection of covid-19 pneumonia on chest ct using multinational datasets","volume":"11","author":"Harmon","year":"2020","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.semcancer.2022.12.009","article-title":"Artificial intelligence-based multi-omics analysis fuels cancer precision medicine","volume":"88","author":"He","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.870842","article-title":"Development and validation of a radiomics nomogram using computed tomography for differentiating immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis for patients with non-small cell lung cancer","volume":"13","author":"Qiu","year":"2022","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0524-2","article-title":"Radiomics to predict immunotherapy-induced pneumonitis: Proof of concept","volume":"36","author":"Colen","year":"2018","journal-title":"Invest New Drugs"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003566","article-title":"Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy","volume":"10","author":"Park","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.764563","article-title":"Immune checkpoint inhibitor and radiotherapy-related pneumonitis: An informatics approach to determine real-world incidence, severity, management, and resource implications","volume":"8","author":"Hindocha","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1109\/rbme.2009.2034865","article-title":"Histopathological image analysis: A review","volume":"2","author":"Gurcan","year":"2009","journal-title":"IEEE Rev BioMed Eng"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e0268954","DOI":"10.1371\/journal.pone.0268954","article-title":"Deep learning-based approach to the characterization and quantification of histopathology in mouse models of colitis","volume":"17","author":"Kobayashi","year":"2022","journal-title":"PloS One"},{"key":"B50","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12967-020-02650-z","article-title":"Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma","volume":"18","author":"Strippoli","year":"2020","journal-title":"J Transl Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1634\/theoncologist.2016-0164","article-title":"Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer","volume":"22","author":"O'Kane","year":"2017","journal-title":"Oncologist"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-019-00456-w","article-title":"Recent advances in the clinical development of immune checkpoint blockade therapy","volume":"42","author":"Ghahremanloo","year":"2019","journal-title":"Cell Oncol (Dordr)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092250","article-title":"Epitranscriptomic approach: To improve the efficacy of icb therapy by Co-targeting intracellular checkpoint cish","volume":"10","author":"Kumar","year":"2021","journal-title":"Cells"},{"key":"B54","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cell.2022.01.008","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"185","author":"Morad","year":"2022","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxaa022","article-title":"Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease","volume":"32","author":"Suzuki","year":"2020","journal-title":"Int Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez465","article-title":"Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors","volume":"58","author":"Ibraheim","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/jci128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J Clin Invest"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590494","article-title":"Distinct immunophenotypes of T cells in bronchoalveolar lavage fluid from leukemia patients with immune checkpoint inhibitors-related pulmonary complications","volume":"11","author":"Kim","year":"2020","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03326-4","article-title":"Ctla-4 blockade drives loss of T(Reg) stability in glycolysis-low tumours","volume":"591","author":"Zappasodi","year":"2021","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0004-4","article-title":"When worlds collide: Th17 and treg cells in cancer and autoimmunity","volume":"15","author":"Knochelmann","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-Pd-1-Based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br J Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004008","article-title":"Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition","volume":"10","author":"Ghosh","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the achilles' heel of cancer immunotherapy","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-0305","article-title":"The role of antigen spreading in the efficacy of immunotherapies","volume":"26","author":"Brossart","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-10-2693","article-title":"Antigen spreading contributes to mage vaccination-induced regression of melanoma metastases","volume":"71","author":"Corbi\u00e8re","year":"2011","journal-title":"Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mrna-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2015.94","article-title":"Genetics of autoimmune diseases: Insights from population genetics","volume":"60","author":"Ramos","year":"2015","journal-title":"J Hum Genet"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxs098","article-title":"Pd-1 is a novel regulator of human b-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/jci96798","article-title":"Early b cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100870","article-title":"Nk cells and ilcs in tumor immunotherapy","volume":"80","author":"Sivori","year":"2021","journal-title":"Mol Aspects Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1172\/jci99317","article-title":"Contribution of nk cells to immunotherapy mediated by pd-1\/Pd-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0012","article-title":"Nccn guidelines insights: Management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(18)30172-3","article-title":"Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy","volume":"6","author":"Rashdan","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the society for immunotherapy of cancer (Sitc) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2019.100834","article-title":"Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature","volume":"27","author":"Petri","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcz224","article-title":"Early infliximab in life-threatening immune-mediated pneumonitis","volume":"112","author":"Cooksley","year":"2019","journal-title":"Qjm"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2019.01032","article-title":"Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-Tnf-A antibody infliximab","volume":"13","author":"Sawai","year":"2019","journal-title":"Drug Discovery Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to pd-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"Il17a blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1802141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031717","article-title":"Ustekinumab for refractory colitis associated with immune checkpoint inhibitors","volume":"384","author":"Anusha","year":"2021","journal-title":"New Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discovery"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01583-1","article-title":"Tralokinumab: First approval","volume":"81","author":"Duggan","year":"2021","journal-title":"Drugs"},{"key":"B90","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/14728214.2022.2031973","article-title":"Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"27","author":"Frieri","year":"2022","journal-title":"Expert Opin Emerg Drugs"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma","volume":"312","author":"Hodi","year":"2014","journal-title":"Jama"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2010419","article-title":"Clinical characteristics of covid-19 in new York city","volume":"382","author":"Goyal","year":"2020","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1053\/j.gastro.2020.10.029","article-title":"Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis","volume":"160","author":"Bishu","year":"2021","journal-title":"Gastroenterology"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800583","article-title":"Efficacy and pharmacodynamic modeling of the btk inhibitor evobrutinib in autoimmune disease models","volume":"202","author":"Haselmayer","year":"2019","journal-title":"J Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.4331\/wjbc.v5.i3.321","article-title":"Mnk kinase pathway: Cellular functions and biological outcomes","volume":"5","author":"Joshi","year":"2014","journal-title":"World J Biol Chem"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: Esmo clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.928390","article-title":"The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy","volume":"12","author":"Bruera","year":"2022","journal-title":"Front Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to pd-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3895","article-title":"Il-12 and il-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: A systematic literature research for the 2019 update of the eular recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0301-1","article-title":"Signaling networks in immunometabolism","volume":"30","author":"Saravia","year":"2020","journal-title":"Cell Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003551","article-title":"Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: From monoclonal antibodies to kinase inhibition","volume":"10","author":"Henderson Berg","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1078155220947141","DOI":"10.1177\/1078155220947141","article-title":"Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases","author":"Liu","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-238851","article-title":"First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis","volume":"14","author":"Murray","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.02.025","article-title":"Immune-related pneumonitis after chemoradiotherapy and subsequent immune checkpoint blockade in unresectable stage iii non-Small-Cell lung cancer","volume":"21","author":"Naidoo","year":"2020","journal-title":"Clin Lung Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1138483\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T05:00:37Z","timestamp":1680584437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1138483\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":109,"alternative-id":["10.3389\/fimmu.2023.1138483"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1138483","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"article-number":"1138483"}}